Thermo Fisher Plummets 1.05% on $630M Trading Volume Ranked 165th as Acquisition Expands U.S. Pharma Manufacturing Footprint

On September 2, 2025, Thermo Fisher Scientific (TMO) saw a 1.05% decline in its share price with a trading volume of $0.63 billion, ranking 165th in market activity. The company recently finalized the acquisition of Sanofi’s advanced sterile fill-finish and packaging facility in Ridgefield, New Jersey, expanding its U.S. manufacturing footprint. The site, now integrated into Thermo’s Laboratory Products and Biopharma Services segment, will enhance capacity to meet rising demand from pharmaceutical and biotech clients.

Thermo’s CEO, Marc N. Casper, highlighted the strategic value of the acquisition, emphasizing the addition of over 200 experienced personnel and the site’s role in strengthening U.S. drug development capabilities. The Ridgefield facility joins existing operations in Greenville, North Carolina, and Plainville, Massachusetts, supporting the company’s Accelerator™ Drug Development 360° CDMO and CRO solutions. This expansion aims to accelerate the delivery of life-changing therapies by optimizing the pharmaceutical value chain for emerging biotech firms.

The transaction, part of a broader strategic partnership with Sanofi, underscores Thermo’s focus on scaling its pharma services business. While financial terms were undisclosed, the move aligns with the company’s $40+ billion annual revenue strategy to provide integrated scientific and pharmaceutical services. Forward-looking statements in the announcement note potential risks, including operational integration challenges and market uncertainties, which could impact future performance.

Thermo Fisher Scientific, a global leader in serving science, continues to prioritize manufacturing network expansion and innovation. The Ridgefield site’s integration is expected to bolster its competitive edge in sterile fill-finish capabilities, catering to the evolving needs of the biopharma industry.